CASE PRESENTATION: A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. This evidence concerns the gene ERBB2 and breast cancer.